The realm of biosimilars is witnessing a significant surge in accessibility and market growth, propelled by innovative treatments, strategic alliances, and competitive market entries that are reshaping patient care across the globe.
In early October 2025, the global biosimilar landscape experienced a notable upturn, driven by a pivotal product launch in the US, strategic collaborations aimed at enhancing affordability, and substantial regulatory milestones for a high-impact asthma and allergy therapy. These developments underscore the persistent endeavors of biopharmaceutical entities to widen patient access and alleviate the financial strain on healthcare systems worldwide.
Celltrion made headlines on October 2, 2025, with the unveiling of its Avtozma (tocilizumab-anoh) intravenous (IV) formulation in the US, introducing a fresh therapeutic option for individuals grappling with severe immune-mediated conditions. Avtozma, positioned as a biosimilar to the reference product Actemra (tocilizumab), secured FDA approval in January 2025. Subsequently, the FDA granted an expanded indication for the IV version in July 2025, allowing its use in adult and pediatric patients aged 2 years and above facing cytokine release syndrome.
This biosimilar now caters to patients across all indications covered by the reference product, encompassing conditions such as rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Moreover, it serves hospitalized adult patients with COVID-19 necessitating oxygen supplementation or more intensive care modalities like mechanical ventilation or extracorporeal membrane oxygenation.
Celltrion’s foray into tocilizumab biosimilars marked its seventh FDA-endorsed biosimilar and its fifth immunology biologic. By acting as an IL-6 receptor antagonist, this drug broadened Celltrion’s immunology portfolio beyond tumor necrosis factor-α and IL-12/23 inhibitors.
In a strategic move to enhance biosimilar accessibility in the Middle East and North Africa (MENA) region, Hikma Pharmaceuticals and its enduring collaborator Celltrion inked exclusive licensing pacts. These agreements revolved around introducing six new biosimilar therapies to MENA markets, aiming to expand access to cost-effective biologics for individuals requiring treatment across vital therapeutic domains including allergic diseases, oncology, immune disorders, ophthalmology, and skeletal-related conditions.
Omalizumab Biosimilar Submissions Intensify Market Competition
Kashiv BioSciences made waves in October 2025 by submitting a biologics license application (BLA) for ADL-018, a proposed biosimilar to Xolair (omalizumab), to the FDA. Concurrently, the European Medicines Agency accepted the marketing authorization application for ADL-018. Omalizumab, a humanized monoclonal antibody, finds application in various conditions such as chronic spontaneous urticaria, moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy.
The market for this therapeutic agent is sizable, with global annual sales of the reference product amounting to approximately $5.5 billion for the 12 months concluding in June 2025, with $4.1 billion in the US and $1.0 billion in the European Union.
Kashiv’s collaboration with Alvotech in developing ADL-018 positions it as a frontrunner among biosimilar entrants in this lucrative market. Amneal Pharmaceuticals anticipates that this product will serve as a significant growth driver, with plans to launch five additional biosimilars between 2026 and 2027, underscoring biosimilars as a pivotal growth engine for the company.
In the convergence of clinical, regulatory, and economic realms, sign up for Center for Biosimilars® emails to access expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes shaping patient care.